Skip to main content
OpenTrials

Clinical trial condition

Blood Protein Disorders

Explore clinical trials studying Blood Protein Disorders. Study availability and eligibility vary by location and protocol.

3,050 public trials 570 recruiting studies
Refine in advanced search Browse all conditions

Blood Protein Disorders trial results

Completed

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

NCT03277105

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Levine Cancer Institute Charlotte, North Carolina, United States
  • Royal Prince Alfred Hospital Camperdown, Australia
  • St Vincents Hospital Melbourne Fitzroy, Australia
View all 146 locations
View Trial Details
Completed

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

NCT03412565

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Cancer Center of Central Connecticut - Southington Southington, Connecticut, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • UF Health Cancer Center at Orlando Health Orlando, Florida, United States
  • Karmonos Cancer Institute Detroit, Michigan, United States
View all 64 locations
View Trial Details
Completed

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

NCT05347485

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • City of Hope Duarte, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Stanford University Medical Center Stanford, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
View all 18 locations
View Trial Details
Completed

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

NCT01998971

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Duarte, California, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Indianapolis, Indiana, United States
View all 22 locations
View Trial Details
Completed

TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT03860038

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Beijing Chao-Yang Hospital,Capital medical university Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Nanfang Hospital of SMU Guangzhou, Guandong, China
View all 18 locations
View Trial Details

Related conditions